There are many things to like about President Donald Trump’s executive order on prescription drugs, which he released last month.

Paramount among them is that it moves the debate over prescription drug pricing away from price controls and other forms of heavy-handed government intervention. Instead, it aims to dismantle many government-imposed barriers that frustrate patients’ ability to access state-of-the-art medicines affordably.

Take the executive order’s treatment of the Medicare Drug Price Negotiation Program created by the 2022 Inflation Reduction Act. This program of price controls is easily the most disastrous bit of health policy in recent memory. It will slow the development of new medicines — and could reduce access to existing ones.

Read more at Newsmax© 2025 Newsmax. All rights reserved.